ARCHIVES

FDA Breakthrough Designation Granted to Pfizer’s Palbociclib

This article is from The Cancer Letter archive.

Vol. 36 No. 4 | April 26, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Rhoads Renamed Cancer Advisory Board Chairman; L-B’s Frederick Contract Renewed For $12 Million

June 28, 1974

NCI Cooperative Groups Begin Trial Of Individualized Rx For Breast Cancer

May 26, 2006

LAK/IL-2 Extramural Trials Expanded to 20 More cancers

January 8, 1988

Bosnian Research Trying To Leave, Asks For More Calls

February 5, 1993

Clinical Cancer Research Battling Threats, Frei Says

May 15, 1981

Contracting Dispute and Software Bugs Plague NCI’s $200 Million Bioinformatics Venture

February 25, 2011